Update on the transition to dolutegravir-based antiretroviral therapy

Übersicht

This technical report summarizes the discussions on the status of programmatic transition to tenofovir, lamivudine and dolutegravir (TLD) in low– and middle- income countries, addressing the best practices and major challenges faced by HIV programmes.

The latest data on safety and efficacy of dolutegravir (DTG) containing regimens were also reviewed. The document identified the remaining gaps in knowledge, research, monitoring, and surveillance on DTG and TLD transition and listed the future priorities.

The primary audiences of this technical report are national HIV programme managers, clinicians, and health care providers. This document will also be of interest to treatment advisory boards, international agencies and organizations that provide technical and financial support to HIV programmes.